Welcome to our dedicated page for Elevation Oncology news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncology stock.
Elevation Oncology, Inc. (Nasdaq: ELEV) is committed to transforming cancer treatment by developing targeted therapeutics tailored to the unique genomic alterations of each patient's tumor. Founded on the belief that every cancer patient deserves to understand the drivers of their disease, Elevation Oncology focuses on making genomic tests actionable by developing drugs to address specific alterations.
The company's prominent clinical candidate, seribantumab, targets tumors driven by NRG1 fusions and is currently undergoing Phase 2 clinical trials in the CRESTONE study. Another pioneering project, EO-3021, is a promising antibody-drug conjugate (ADC) focusing on Claudin 18.2-expressing cancers. EO-3021 is designed to selectively deliver a payload to cancer cells, minimizing collateral damage to healthy cells. The U.S. FDA has cleared an Investigational New Drug application for EO-3021, and the Phase 1 clinical trial has already commenced in the United States and Japan.
In addition to its robust pipeline, Elevation Oncology has received strategic backing from prominent investors such as Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners. This financial support underscores the confidence in the company's innovative approach and potential for significant impact on cancer treatment.
The latest news includes the announcement from August 3, 2023, revealing financial results for the second quarter of 2023 and highlighting the successful public offering of $46.5 million in net proceeds. Additionally, as of June 30, 2023, Elevation Oncology holds cash reserves of $107.9 million, sufficient to fund operations into the second half of 2025. Furthermore, the first patient has been dosed in the Phase 1 trial for EO-3021, with promising initial data expected by mid-2024.
Elevation Oncology continues to advance its pipeline with a vision to expand treatment options through new and existing partnerships. The company’s focus on precision medicine aims to deliver better outcomes for patients with significant unmet medical needs, reaffirming its commitment to innovation and patient-centered care.
Elevation Oncology has announced the selection of an abstract for SYSA1801 (EO-3021) Phase 1 clinical data for presentation at the ASCO 2023 Annual Meeting in Chicago, from June 2-6, 2023. The ongoing Phase 1 study is focused on evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors, conducted in partnership with CSPC Pharmaceutical Group in China. Elevation plans to advance its clinical trial for EO-3021 in the U.S. in the second half of 2023. EO-3021 targets Claudin 18.2, a significant unmet need in oncology, particularly for gastric and pancreatic cancers, with no existing approved therapies. The U.S. FDA has cleared an Investigational New Drug application for EO-3021.
FAQ
What is the current stock price of Elevation Oncology (ELEV)?
What is the market cap of Elevation Oncology (ELEV)?
What is Elevation Oncology's main focus?
What is seribantumab?
What is EO-3021?
Who are Elevation Oncology's key investors?
What recent financial achievements has Elevation Oncology announced?
Where is EO-3021 being tested?
What is the purpose of Elevation Oncology's clinical trials?
How does Elevation Oncology approach drug development?
What are Elevation Oncology’s financial expectations?
What was announced during the ASCO 2023 meeting?
